Discover
RGLS
Regulus Therapeutics Inc.
8.16
undefined x undefined
undefined x undefined
bid
ask
+
0.00
0.00%
04:00 PM
| Ytd | 416.46% | |
| 1y | 298.05% |
8.16
day range
8.16
52 week range
| Open | 8.15 | Prev Close | 8.16 | Low | 8.16 | High | 8.16 | Mkt Cap | N/A |
| Vol | 8.76M | Avg Vol | 0.00 | EPS | N/A | P/E | N/A | Forward P/E | -1.26 |
| Beta | 1.63 | Short Ratio | 3.38 | Inst. Own | 88.26% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | N/A | 200-d Avg | N/A | 1yr Est | 10.33 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-07 | 2024-09 | -0.18 | -0.21 | -0.03 | -16.67% |
| 2024-08-08 | 2024-06 | -0.17 | -0.17 | N/A | N/A |
| 2024-05-09 | 2024-03 | -0.15 | -0.29 | -0.14 | -93.33% |
| 2024-03-21 | 2023-12 | -0.4 | -0.4 | N/A | N/A |
| 2023-11-09 | 2023-09 | -0.36 | -0.4 | -0.04 | -11.11% |
| 2023-08-08 | 2023-06 | -0.39 | -0.37 | 0.02 | 5.13% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-11 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-10-30 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-14 | Oppenheimer | Upgrade | Outperform | Outperform |
| 2024-08-09 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-07-16 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-06-25 | Canaccord Genuity | Upgrade | Buy | Buy |
Profile
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-01-17 | AKER CHRISTOPHER RAY | General Counsel | 10.06K | Sale |
| 2024-01-17 | CALSADA CRISPINA CPA | Chief Financial Officer | 5.78K | Sale |
| 2024-07-24 | COLLIER KATHRYN J. | Director | 6.74K | Purchase |
| 2024-01-17 | HAGAN JOSEPH PATRICK | Chief Executive Officer | 57.11K | Sale |
| 2024-03-13 | PAPADOPOULOS STELIOS B | Director | 978.39K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Federated Hermes, Inc. | 12.85M | 19.66M | 19.62% |
| 2024-09-29 | NEA Management Company, LLC | 6.47M | 9.90M | 9.87% |
| 2024-09-29 | Vivo Capital, LLC | 5.00M | 7.65M | 7.63% |
| 2024-09-29 | Octagon Capital Advisors LP | 4.26M | 6.52M | 6.51% |
| 2024-09-29 | Vanguard Group Inc | 4.09M | 6.26M | 6.24% |
| 2024-09-29 | Blackrock Inc. | 4.08M | 6.24M | 6.23% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-07-30 | Federated Hermes Kaufmann Fund | 7.88M | 12.06M | 12.03% |
| 2024-07-30 | Federated Hermes Kaufmann Small Cap Fund | 7.42M | 11.35M | 11.32% |
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 2.50M | 3.83M | 3.82% |
| 2024-10-30 | iShares Russell 2000 ETF | 1.62M | 2.48M | 2.47% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 1.13M | 1.73M | 1.73% |
| 2024-07-30 | USAA Mutual Fund Tr-Science & Technology Fund | 937.81K | 1.43M | 1.43% |
Split
| Split | Date |
|---|---|
| 1 : 10 | 2022-06-29 |
| 1 : 12 | 2018-10-04 |